Read the latest insights from #GU26 From genomic predictors to real‑world combination strategies, experts highlight TP53 status as a potential marker of benefit, broad activity across disease features, and evolving mCRPC approaches ow.ly/tuHe50Ypb0U #ASCOGU #ASCOGU2026 #MedEd #MedSky

It’s News‑day Tuesday! Does intensifying treatment improve outcomes? At #GU26, Karim Fizazi unpacks first PEACE‑2 results—finding no clinical benefit beyond long‑term ADT + radiotherapy in very high‑risk localized prostate cancer ow.ly/sQ9G50Yoxrz

What’s holding back routine HRR testing in #ProstateCancer care? Watch Arun Azad unpack common misconceptions, real‑world workflow challenges, and why education is critical to ensuring patients don’t miss access to PARP inhibitors. ow.ly/lbgr50Yoatp #MedEd #Oncology #MedSky

That’s a wrap for this oral abstract session on IMvigor011 trial at #GU26 Missed any insights? Explore on demand congress coverage and expert perspectives on Medthority ow.ly/zJpy50Yn3UP

Dr. Bellmunt concludes IMvigor011: 🧬 Detectable ctDNA after RC identified higher‑risk pts, while persistent ctDNA− aligned with low risk 💉 Adjuvant atezolizumab promoted ctDNA reduction and clearance which was associated with improved DFS #GU26 #BladderCancer #MIBC

🔬 Dr. Bellmunt presents IMvigor011: early ctDNA positivity after RC was frequent and typically detected within <24 wks 📉Baseline ctDNA levels differed by risk group, and ctDNA kinetics showed clear divergence between arms over time #GU26 #BladderCancer #MIBC #Oncology

Can ctDNA timing and dynamics refine adjuvant treatment decisions in #MIBC? Follow our #GU26 coverage for new insights from Joaquim Bellmunt on the IMvigor011 trial #BladderCancer #Oncology #MedSky #MedEd

That concludes our live coverage on the KEYNOTE-B15 trial. Stay tuned for the oral abstract session on the IMvigor011trial starting at 16:57 BST/08:57 PST 🕔

Matthew D. Galsky concludes neoadjuvant + adjuvant EV+pembro improved EFS, OS and pCR vs cis+gem in cisplatin‑eligible MIBC 📈 Efficacy appeared consistent across subgroups and no new safety signals were seen Findings support EV+pembro as a novel option in MIBC #GU26 #BladderCancer

KEYNOTE‑B15: EV + pembro shows strong EFS benefit in cisplatin‑eligible MIBC HR 0.52; 12‑mo EFS 78.2% vs 64.0% with chemo Matthew D. Galsky notes “The EV+pembro and cis+gem curves separate at ~6 months and stay apart” ✅EFS significantly longer with EV+pembro #GU26 #Oncology #MIBC

We’re back with more #GU26 coverage! Today we kick-off with the latest results from the KEYNOTE-B15 study presented by Matthew D. Galsky #BladderCancer #Oncology #MIBC #MedEd #MedSky

That wraps up our live coverage of #GU26 sessions on #mCRPC! From PEACE‑3 to BRCAAway, today’s discussions highlighted how combination strategies are reshaping overall survival in #mCRPC For more congress coverage, visit the Prostate Cancer Nexus on Medthority ow.ly/yCG750YmtgI

Key takeaways from BRCAAway: 🔹 A + O showed longest OS (46.2 mo) 🔹 Strongest 24‑ & 36‑mo OS landmarks 📈 🔹 AEs manageable; A + O maintained acceptable tolerability 🔹 Supports continued evaluation of PARPi + ABI in DDR‑mutated mCRPC #GU26 #mCRPC #ProstateCancer #Oncology

Dr. Hussain presents OS results from the BRCAAway trial in first‑line #mCRPC with DDR defects: 🔹 Abiraterone, olaparib, or the combination in BRCA1/2/ATM 🔹 Median OS longest in Arm 3 (A+O): 46.2 mo 🔹 Arm 3 showed highest 24 & 36‑mo OS 📊 #GU26 #ProstateCancer #Oncology

What’s next for overall survival optimization in #mCRPC? Following the PEACE‑3 final OS results with enzalutamide + radium‑223 from Enrique Gallardo, the conversation continues with Maha HA Hussain and the BRCAAway OS data at #GU26.

🗝 Key takeaway points from PEACE‑3: 📈 ENZA + 6 cycles Rad‑223 improves OS ⚠️ No new safety signals; moderate AE increase 💊 “ENZA + Rad‑223 (with BPA) is an option in first‑line mCRPC with bone metastases” #GU26 #Oncology #MedEd #mCRPC #ProstateCancer #MedSky

Dr. Gallardo shares final data from PEACE‑3 (Enzalutamide ± Radium‑223) in mCRPC with bone mets: 🔹 Significant OS benefit with ENZA + Rad‑223 🔹 rPFS improvement confirmed 📈 🔹 Moderate ↑ in AEs #GU26 #mCRPC #ProstateCancer #Oncology

How have combination strategies reshaping overall survival in #mCRPC? Join our #GU26 coverage as Enrique Gallardo and Maha HA Hussain discuss the latest overall survival results from the EORTC 1333/PEACE‑3 and BRCAAway trials. #ProstateCancer #Oncology #OncTwitter #MedEd #MedSky

We're at #GU26! Stay informed on the latest research in #ProstateCancer and #BladderCancer with our live coverage from the event, plus keep an eye out for summary articles, free and on demand with Medthority 👀 #MedSky #ASCO #ASCOGU ow.ly/HUNu50Ymiw3

📰 It’s News-day Tuesday! Scientists uncover how low‑oxygen conditions turn red blood cells into “glucose sponges,” opening the door to new diabetes treatments. Plus, new research shows brain cells are key to building exercise endurance. #MedEd #MedSky ow.ly/MgWz50YkTk0

Stronger PSA suppression leads to improved outcomes in mHSPC, new study finds. Read our summary article on Medthority now for more insights on how this simple biomarker can have powerful prognostic value #MedSky #ProstateCancer #MedEd ow.ly/QFbL50Ykebx

📰 It’s news‑day Tuesday! A new experimental drug has doubled survival for women with treatment‑resistant ovarian cancer in a recent trial. Plus, AI shows promise in detecting placenta accreta spectrum, a dangerous pregnancy complication. #MedEd #MedSky ow.ly/2sXH50YgWmi

New insights from #WORLDSymposia 2026 are shaping how we think about #LysosomalDiseases. Our latest research update explores how early biomarker and symptom patterns in newborn‑screened infants may help guide #PompeDisease treatment decisions #MedSky ow.ly/5X7Q50YgCLc

This #InternationalDayOfWomenAndGirlsInScience, we want to celebrate our exceptional all-female writing team! With experience across all 15 specialties, they help us bring you closer to the conversations that matter in your field #MedSky #MedEd #WomenInSTEM ow.ly/6lKv50YcJIf

📰 It's News-day Tuesday! Women vaccinated against HPV need fewer cervical cancer screenings in their lifetime, plus new data reveals the impact of the COVID-19 pandemic on cancer survival in the US. Read the latest #MedicalNews now on Medthority #MedSky #MedEd ow.ly/ksA150Yc70t

If you enjoyed #ACTRIMSForum 2026 over the weekend, why not review our resources on multiple sclerosis (MS) to catch up with the guideline updates and latest news you need to know #MedSky #ACTRIMS #MS #MultipleSclerosis #MedEd ow.ly/Fb7650YbGNV

This #WorldCancerDay, browse our Oncology Hub for the latest advances and congress highlights in genitourinary, respiratory, and sarcoma oncology, from assessing patient risk of disease recurrence to identifying unmet needs #MedSky #MedEd #OncSky ow.ly/U6hj50Y8SXr

📰It's news-day Tuesday! Colon cancer has become the leading cause of cancer-related deaths in American adults under 50. Plus, can exposure to wildfire smoke during pregnancy increase the risk of an autism diagnosis? #MedSky #MedicalNews #MedEd ow.ly/Ms4T50Y823b

How can we mitigate potential risks in #NMIBC treatment? Morgan Rouprêt shares his thoughts at #ESMO2025, including incorporating pathological assessment into treatment selection. For more congress highlights and the latest trial data, head to Medthority now #MedSky #OncSky ow.ly/EyRT50Y5WZ4

New research has uncovered the pathway that causes uncontrolled inflammation in obesity, plus messenger RNA in the uterus cell lining might lead to future treatments for some forms of infertility. Get the latest #MedicalNews on Medthority #MedSky #MedEd ow.ly/lmRV50Y5vcJ

Only 1 month to go until #GU2026! Get ready with a quick recap on key #ProstateCancer highlights from #GU2025 on Medthority, including expert insights on a new treatment option for HRR-deficient #mCRPC and our posters round-up #MedSky #MedEd #OncSky ow.ly/Ytna50Y4UVE

What can primary care providers do to support earlier diagnosis of AATD-associated #LiverDisease? Watch James Stoller challenge common misconceptions about the diagnostic process and highlight education gaps that impact real-world practice #MedSky #LiverSky #MedEd ow.ly/bJXb50Y3P99

Tomorrow is #InternationalDayofEducation! Even if you only have 10 minutes to spare, get the latest updates in your field with Medthority's independent resources. You can browse by therapy area using the link to our Speciality Hub below #MedSky #MedEd ow.ly/zcIv50Y1Nu3

📢 New research validates the EHR-CAT score for more accurate risk classification, supporting scalable #VTE assessment in routine #Oncology practice. Read the latest news article from our expert team now #MedSky #MedEd #MedicalNews #CardioSky #OncSky ow.ly/ihHQ50Y1fj1

Have you watched our on-demand roundtable covering insights from 2025 #Thrombosis #TrialData? From reduced-dose anticoagulation strategies to evolving approaches in #AF and #VTE, stay ahead in thrombosis care with Medthority #MedSky #CardioSky #HaemSky ow.ly/KFJA50Y0Jf8

From #Alopecia and #Psoriasis to #HidradenitisSuppurativa and #Urticaria, check out our #Dermatology Hub for podcasts, quizzes, roundtables, and many more expert resources designed to support your clinical practice #MedSky #DermSky ow.ly/W2Yu50XZY3S

📰It's news-day Tuesday! First human coronary bypass surgery has been performed without chest cracking 🫀 Plus, researchers can now track aggressive cancer in blood thanks to newly identified tumor cell characteristics #MedSky #MedEd #MedicalNews ow.ly/qck350XZYcB

As the treatment landscape for #NMIBC continues to evolve, get the insights you need to know with Medthority. Log in to hear from Joshua Meeks, Félix Guerrero-Ramos, and @ashishkamatmd.bsky.social, plus catch up with highlights from #ESMO25, #ASCO25, and more! #MedSky #OncSky ow.ly/mFcc50XZKzO

Help us continue to improve #MedicalEducation in 2026 by taking our quick survey! If you have 5 minutes, share your insights with us today and help shape the future of learning for healthcare professionals worldwide 🌍 #MedSky #MedEd ow.ly/ZmZx50XXY3f

Overcome challenges in diagnosing and managing #AATD #LiverDisease with Medthority. Earn up to 2.5 #CME credits now with accessible resources designed to suit you, whether you like to read, watch, or listen #MedSky #Hepatology #MedEd #LiverSky ow.ly/n8wu50XXjj9

How much do you know about overlooked symptoms and unmet needs in #LOPD? Take a quick quiz before watching our accredited symposium recording on real-world data and the impact of patient insights to earn 1 #CME credit today #MedSky #NeuroSky #MedEd ow.ly/j7HC50XWN8a

Tune in to the latest episodes of our #PodcastSeries to hear from Henry Kaminski and Nils Erik Gilhus on the evolving #MG treatment landscape, from targeted therapies to management challenges, plus the digital innovation shaping the future of care #MedSky #MedEd ow.ly/1OVv50XWeT7

📰It's news-day Tuesday! Can yoga help with opioid withdrawal?🧘‍♀️Plus, newly identified biomarkers may help more accurate diagnosis of type 2 diabetes in African populations. Get the #MedicalNews you need to know now on Medthority #MedSky #MedEd ow.ly/JpbO50XW5k6

Get closer to the conversations that matter in #ProstateCancer with our research round-ups, providing the updates you need to know, all in one place. Visit Medthority for #TrialData summary articles, expert interviews, and key congress takeaways #MedSky #OncSky ow.ly/QPTv50XVEmW

Demystify #ChronicInflammatoryDemyelinatingPolyneuropathy (CIDP) with Medthority. Get expert perspectives from Eduardo Nobile-Orazio, plus #GuidelineUpdates on diagnostic barriers and long-term complications to support your clinical practice #MedSky #NeuroSky #MedEd ow.ly/Vg5g50XTYyz

Overcome challenges with diagnosing and managing neurofibromatosis type 1 (NF1) with insights from #EANO2025. Read about treatment advances, trial updates, and what's next for care #MedSky #OncSky #NeuroSky #MedEd ow.ly/BPNU50XTwj0

Listen to Arash Mostaghimi and Ursula Biba explore the psychosocial burden of #AA on patients, from the importance of asking "How is this impacting you?" to new guidelines redefining disease severity with psychosocial impact in mind #MedSky #DermSky #AlopeciaAreata ow.ly/rKv550XSZ8t

Catch up with the #MedicalNews you might have missed over the festive period 📰 From a new study on reducing incidence of malaria in children to the impact of political pressures on research grants, head to Medthority now for the updates you need #MedSky #MedEd ow.ly/138J50XSlai

Are you up to date with the latest strategies in managing #ChronicSpontaneousUrticaria (CSU)? Visit Medthority now for #Guideline recommendations, #CongressHighlights, and expert perspectives on the future of CSU treatment #MedSky #MedEd #DermSky ow.ly/EytH50XS0It

Overcome diagnostic challenges in HLH/MAS with our expert resources. Earn CME credit with our masterclass from Fabrizio de Benedetti, catch up with highlights from ACR 2025, and tune in to our podcast series hosted by Michael Jordan, all available on demand now #MedSky ow.ly/gAPk50XLmE4